Anticoagulation Management

Initiation of Anticoagulation

Initial warfarin dosing is recommended at 5-10 mg daily for the first 2 days, then adjusted based on INR, as suggested by the American Thoracic Society and the British Thoracic Society 1
Unfractionated heparin should be administered with an initial IV bolus of 5,000-10,000 IU, followed by a continuous IV infusion of 1,300 IU/hour, with a target aPTT of 1.5-2.5 times control, as recommended by the European Society of Cardiology 2

For patients with high-risk pulmonary embolism (PE) and hemodynamic instability, the European Society of Cardiology recommends starting parenteral anticoagulation immediately and considering thrombolysis if appropriate, then transitioning to oral anticoagulation only after the patient is stabilized 3
Thrombolytic therapy, such as rtPA, streptokinase, or urokinase, may be considered for patients with significant hypoxemia or hypotension due to proven pulmonary embolism, as recommended by the British Thoracic Society 1
Catheter-directed thrombolysis delivers a lower total dose of thrombolytic, typically 20-24 mg alteplase, approximately one-fourth of the systemic dose, as reported in Circulation 4
The clinical success rate of catheter-directed thrombolysis is approximately 87%, as defined by stabilization of hemodynamic parameters, resolution of hypoxia, and survival to discharge, according to the European Heart Journal 5

The American Thoracic Society and the British Thoracic Society recommend monitoring INR regularly to maintain a target of 2.0-3.0 for patients on warfarin 1
Patients with pulmonary embolism should be monitored regularly to assess for medication adherence, bleeding complications, and signs of chronic thromboembolic pulmonary hypertension, with regular INR monitoring for patients on warfarin, according to the British Thoracic Society 1
Routine clinical evaluation is recommended at 3-6 months after acute pulmonary embolism, with a Class I recommendation from the European Respiratory Society 6
Regular clinical follow-up at 3-6 months is essential to assess medication adherence, bleeding complications, signs of chronic thromboembolic pulmonary hypertension (CTEPH), and need for extended anticoagulation, as recommended by the American College of Chest Physicians and the European Society of Cardiology 7, 3, 6

The recommended duration of anticoagulation varies by patient population, as outlined in the following table:
Patient Population Recommended Duration
Secondary PE due to transient/reversible risk factors 3 months
Unprovoked PE or persistent risk factors Extended (>3 months)
Recurrent PE Indefinite
8, 3, 1
Low molecular weight heparin (LMWH) is preferred over unfractionated heparin (UFH) for most patients with acute pulmonary embolism due to its comparable efficacy, lower risk of major bleeding, and more predictable pharmacokinetics, as recommended by the British Thoracic Society and supported by multiple systematic reviews 9, 10

Patient Population	Recommended Duration
Secondary PE due to transient/reversible risk factors	3 months
Unprovoked PE or persistent risk factors	Extended (>3 months)
Recurrent PE	Indefinite

The recommended dosing regimens for DOACs are:

DOAC	Dosing Regimen
Apixaban	10 mg twice daily for 7 days, followed by 5 mg twice daily
Rivaroxaban	15 mg twice daily for 21 days, followed by 20 mg once daily
Dabigatran	150 mg twice daily after initial LMWH
Edoxaban	60 mg once daily (30 mg once daily if CrCl 30-50 mL/min or body weight <60 kg)

Cancer patients should receive Low Molecular Weight Heparin (LMWH) for at least 6 months, followed by continued anticoagulation while cancer is active, as recommended by the European Society of Cardiology 3
Pregnant patients should receive LMWH as the treatment of choice, with Direct Oral Anticoagulants (DOACs) and vitamin K antagonists being contraindicated, according to the European Society of Cardiology 3, 7
Patients with severe renal impairment (CrCl <30 mL/min) should preferentially receive UFH, followed by VKA, while hemodynamically unstable patients should receive UFH due to its short half-life and reversibility 3
For pregnant women with high-risk pulmonary embolism, thrombolysis or surgical embolectomy should be considered, with a Class IIa recommendation from the European Respiratory Society 6

Surgical embolectomy is a recommended alternative option for patients who fail or are contraindicated for systemic thrombolysis, with a Class IIa recommendation from the European Respiratory Society 6
Catheter-directed treatment is also a recommended alternative option for patients who fail or are contraindicated for systemic thrombolysis, with a Class IIa recommendation from the European Respiratory Society 6
Vena cava filters are associated with a significantly increased risk of recurrent deep vein thrombosis and may reduce PE-related mortality in the acute phase, but this comes at the cost of increased risk of recurrent VTE 10, 12
The occlusion rate of vena cava filters can be as high as 15% without anticoagulation, compared to only 8% with anticoagulation 2